Tell your doctor or nurse as soon as you have any side effects or notice anything that seems out of the ordinary while taking ZYDELIG, even if it isn't a side effect listed on this website.
Side effects can occur at any time. The earlier your treatment team learns about potential side effects you’re experiencing, the better chance they have to address the side effect and ensure ZYDELIG is still the most appropriate treatment for you. If addressed early, many side effects related to ZYDELIG can be managed.2
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You can also call 1-800-GILEAD-5 (1-800-445-3235).
ZYDELIG is approved for use in follicular B-cell non-Hodgkin lymphoma when the disease worsens after treatment with at least 2 prior medicines. ZYDELIG was approved based on response rates. Data are not yet available to show if ZYDELIG improves symptoms or survival.
ZYDELIG is approved for use in combination with Rituxan® (rituximab) when CLL comes back after prior cancer treatment and when Rituxan treatment alone may be used due to other health problems.
ZYDELIG is approved for use in small lymphocytic lymphoma (SLL) when the disease worsens after treatment with at least 2 prior medicines. ZYDELIG was approved based on response rates. Data are not yet available to show if ZYDELIG improves symptoms or survival.
ZYDELIG should not be used as the first medicine to treat people who have been diagnosed with CLL, follicular lymphoma, or SLL, and should not be used in combination with bendamustine and/or Rituxan to treat people with follicular lymphoma.